LivaNova 8th Annual Wolfe Research Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. Good morning. Welcome to day two of the Wolfe Research Healthcare Conference. My name is Mike Polark, medical device analyst here at Wolfe Research. Pleased in this session to be joined by LivaNova. From the company, we have CEO Vlad Makatsaria and Chief Innovation Officer Ahmet Tezel. Vlad and Ahmet, good to be with you. Thanks for being here. Good morning.
Well, good morning, Mike and everybody, good morning, and thank you for the opportunity to join you this morning.
Maybe, Vlad, I will just pass it to you to start to set the stage, reflections on 2026 so far, highlights, challenges to the extent they are worth mentioning, and top few priorities as you roll into 2027. What are you most focused on for the company across the divisions?
Thank you for the question. I am going to assume most of you know the LivaNova story, but if you do not, we have two businesses that are leaders in their market. One is epilepsy and its treatment of drug-resistant epilepsy with neuromodulation, and the other side of the business is a cardiopulmonary business, so it is perfusion during open-heart surgery, surgical procedure. Both of these businesses are leaders in their space. We are in the process of launching obstructive sleep apnea business with proximal hypoglossal nerve stimulation, so that is on track for the launch next year. Then we have upside optionality with our difficult-to-treat depression business that is also hypoglossal nerve stimulation, so neuromodulation-based business. One thing that I am really pleased with the progress this year is with the quality of our growth.
We have delivered now several, actually three years of double-digit growth, but what I am really pleased with this year is this growth is very balanced. It is balanced between neuromodulation or epilepsy side and cardiopulmonary. Both businesses are growing double digit. I am pleased with our performance across various regions around the world, U.S., Europe, Asia Pacific, Latin America, so it is well-balanced geographically. Even within businesses, like for example, in cardiopulmonary, our growth historically has been dominated by heart-lung machines. Now you see a much more balanced growth between heart-lung machines and oxygenators. On the epilepsy front, the growth is driven both by price, volume, by new patients, by replacements. That kind of quality of growth and well-balanced growth gives us more confidence in the sustainability of that growth moving forward.
As we enter 2027, the focus remains consistent. One is on building a strong team, focusing on our culture. That is number one. Make sure that the growth is at the forefront of everything we do and continue driving growth. Innovation agenda, oxygen for our future, and making sure that both in the core businesses, but also our new categories that we are executing well versus our plans on innovation front and that culture of innovation is thriving. Then finally, execution is to make sure that we do everything efficiently and we continue to generate strong operating margins and cash.
Good setting of the stage. Thank you, Vlad. Let us go cardiopulmonary to start. We will do epilepsy, and then we will get into sleep apnea, and maybe a quick question on depression at the end. In cardiopulmonary, I will ask it through the lens of into 2027. I think Essenz goes from 80% of shipments this year to probably 100%. That is an embedded revenue growth tailwind on mix. Oxygenators, you have just announced a new, or completion of, I believe, a major manufacturing expansion, provides volume tailwinds for the consumable side, and maybe even heater-cooler and air manager, those modules will start rolling out at some point next year. Have I characterized the drivers correct, and which of those incrementally relative to the last few years of really good cardiopulmonary growth is even more impactful next year?
Maybe I'll start with the growth drivers, then I'll turn it over to Ahmet to talk a bit more about the innovation and the roadmap ahead of us. On the cardiopulmonary, you characterized the growth drivers very well. I would add maybe one more is price to that. Maybe start with oxygenators. In cardiopulmonary, about one-third of our business is equipment-based. It's heart-lung machines. About two-thirds of the business are disposables, and within disposables, oxygenators are the most differentiated and meaningful part of the portfolio. In oxygenators, it's a mature market, but we were able to gain about 10 points of share in the last couple of years. We went from 30% to 40%, and we have strong confidence in our ability to continue growing that market share, driven by three things.
One is commercial excellence, two is our ability to supply better, and three, innovation, which Ahmet will talk about. On the supply has been the key driver, and the reason for that is that the procedures themselves went from low single-digit growth to mid-single-digit growth over the past few years. We see that that mid-single-digit growth is sustainable moving forward, given the demographics, dynamics, and also some of the patients that used to have minimally invasive procedures are now coming back for more advanced type of surgery. That really drove the fact that the demand for the oxygenators is higher than the market's ability to supply. We've been focused on significantly improving our outputs on manufacturing.
The last two big milestones was our long-term partnership with Thermo Fisher in terms of supply agreement of a key component for oxygenators that removes that as a barrier moving forward. Also, in October specifically, we opened a new manufacturing line in our own facility for oxygenators, and that manufacturing line gives us an opportunity to continue with double-digit output growth into 2027. That's oxygenators. On heart-lung machines, again, we launched a new heart-lung machine a couple of years ago, and we've been gradually upgrading our fleet into this new machine called Essenz. This year, 80% of all heart-lung machines we placed were new ones or Essenz ones. Next year, 100% of our placements will be Essenz. If you look at the broader market, we have 70% market share approximately in heart-lung machines.
That translates in about 10,000 units placed out there, and only about 20% of those units today are Essenz. It gives us still a significant runway, and maybe we won't get that price mix impact after 2027. We can still play on volume growth as we have the significant opportunity to upgrade the remaining fleet of equipment. Then you talked a little bit about heater-cooler and air manager, those are modules into the heart-lung machines. We launched that new Essenz machine with old modules, so we are due to upgrade those. As of next year, we will start getting regulatory approvals for air manager and heater-cooler. It will start in Europe, and then it will gradually expand in other parts of the world, but the more meaningful growth will come in 2028. Ahmet, maybe comment on innovation.
Yeah, I mean, we are excited about three main pieces that Vlad talked about. The oxygenator launch that will happen in 2028. We are really excited about it because out of the 10 parameters that perfusionists care about in the performance of an oxygenator, this will become the best in class in all 10. We already have that kind of share momentum happening. We believe it will just fuel it. It is a highly differentiated oxygenator. It will not compete in terms of capacity with the existing oxygenator because it is in a different part of the plant in Italy, so we also like that fact. I would think of the air manager and heater-cooler, like if Essenz was a performance car, which it is, these will be like the tires or the gasoline that you put in it.
It just elevates the performance of Essenz because they are allowing Essenz to perform at its peak capacity, the air manager and heater-cooler. That is why we are, from a technology standpoint, think that when we launch those products, Essenz is just going to perform even better in terms of its technical abilities.
I will pull one follow-up, and then we can move to epilepsy. I think the oxygenator market, just an interesting one, two-parter. Do you still have any surprise that your competitors have not responded in the way that you seem to be responding? Any evidence that that could change, or no, this is LivaNova's market to win in? That is question one. Then two is just this sustaining a double-digit increase in output. That is volume, and there is still positive price. I just want to confirm that as an expectation as you roll into 2027.
Yeah, so maybe start with the end of the question. Absolutely, so it is volume and price, and I think one of LivaNova's strong capabilities is strategic pricing, and so absolutely price is going to play a role in that. Regarding the market itself, I think we were all surprised with elevation of procedure growth, and that caught us by surprise a few years ago. This is the market where scale matters, because it is high capital intensity, it is very high volume, it is relatively low value in terms of unit sales, and then that type of market scale matters. Now that we have approximately 40% market share, it just makes us more competitive purely from scale point of view. Then we saw some of the competitors exit for that exact reason, that Getinge, for example, had about 5% market share.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
